Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal

被引:441
作者
Tsuruo, T
Naito, M
Tomida, A
Fujita, N
Mashima, T
Sakamoto, H
Haga, N
机构
[1] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan
[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan
关键词
D O I
10.1111/j.1349-7006.2003.tb01345.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent progress in the development of molecular cancer therapeutics has revealed new types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for specific tumors. Our work has focused on molecular cancer therapeutics, mainly in the areas of drug resistance, apoptosis and apoptosis resistance, and survival-signaling, which is related to drug resistance. In this review, we describe our research on molecular cancer therapeutics, including molecular mechanisms and therapeutic approaches. Resistance to chemotherapeutic drugs is a principal problem in the treatment of cancer. P-Glycoprotein (P-gp), encoded by the MDR1 gene, is a multidrug transporter and has a major role in multidrug resistance (MDR). Targeting of P-gp by small-molecular compounds and/or antibodies is an effective strategy to overcome MDR in cancer, especially hematologic malignancies. Several P-gp inhibitors have been developed and are currently under clinical phased studies. In addition to the multidrug transporter proteins, cancer cells have several drug resistance mechanisms. Solid tumors are often placed under stress conditions, such as glucose starvation and hypoxia. These conditions result in topo 11 poison resistance that is due to proteasome-mediated degradation of DNA topoisomerases. Proteasome inhibitors effectively prevent this stress-induced drug resistance. Glyoxalase 1, which is often elevated in drug- and apoptosis-resistant cancers, offers another possibility for overcoming drug resistance. It plays a role in detoxification of methylglioxal, a side product of glycolysis, which is highly reactive with DNA and proteins. Inhibitors of glyoxalase I selectively kill drug-resistant tumors that express glyoxalase 1. Finally, the susceptibility of tumor cells to apoptosis induced by antitumor drugs appears to depend on the balance between pro-apoptotic and survival (anti-apoptotic) signals. PI3K-Akt is an important survival signal pathway, that has been shown to be the target of various antitumor drugs, including UCN-01 and geldanamycin, new anticancer drugs under clinical evaluation. Our present studies provide novel targets for future effective molecular cancer therapeutics.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 52 条
[1]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[2]   The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis [J].
Bachelder, RE ;
Wendt, MA ;
Fujita, N ;
Tsuruo, T ;
Mercurio, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (37) :34702-34707
[3]   Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 [J].
Basso, AD ;
Solit, DB ;
Munster, PN ;
Rosen, N .
ONCOGENE, 2002, 21 (08) :1159-1166
[4]  
Brown JM, 1998, CANCER RES, V58, P1408
[5]   Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release [J].
Fontana, J ;
Fulton, D ;
Chen, Y ;
Fairchild, TA ;
McCabe, TJ ;
Fujita, N ;
Tsuruo, T ;
Sessa, WC .
CIRCULATION RESEARCH, 2002, 90 (08) :866-873
[6]   Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization [J].
Fujita, N ;
Sato, S ;
Katayama, K ;
Tsuruo, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (32) :28706-28713
[7]   Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1 [J].
Fujita, N ;
Sato, S ;
Ishida, A ;
Tsuruo, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (12) :10346-10353
[8]   Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cδ [J].
Godbout, JP ;
Pesavento, J ;
Hartman, ME ;
Manson, SR ;
Freund, GG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (04) :2554-2561
[9]  
HAMADA H, 1990, CANCER RES, V50, P3167
[10]   FUNCTIONAL-ROLE FOR THE 170-KDA TO 180-KDA GLYCOPROTEIN SPECIFIC TO DRUG-RESISTANT TUMOR-CELLS AS REVEALED BY MONOCLONAL-ANTIBODIES [J].
HAMADA, H ;
TSURUO, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (20) :7785-7789